Fujifilm SARS-CoV-2antigen Test Kit Using Silver Amplification Immunochromatography Method

Fujifilm applies for manufacturing and marketing approval for a SARS-CoV-2antigen test kit using silver amplification immunochromatography method*
Capital investment for Vietnam production site decided, to provide a stable global supply
TOKYO, December 17, 2020 — FUJIFILM Corporation (President: Kenji Sukeno) is pleased to announce that it has filed an application with the Pharmaceuticals and Medical Devices Agency to obtain manufacturing and marketing approval for a rapid and simple antigen test kit for detecting SARS-CoV-2, using silver amplification immunochromatography method*, as in-vitro diagnostic medical device. This kit has been developed with the use of highly-sensitive detection technology based on silver halide amplification response used in the photo-developing process.

In a bid to establish a production structure for this test kit, Fujifilm is making a capital investment in FUJIFILM YUWA MEDICAL PRODUCTS VIETNAM COMPANY LIMITED (Head office in Bình Dương, Vietnam), which manufactures Fujifilm’s diagnostics medical products. The investment has been chosen for the third round of a business support program by the Japan External Trade Organization (JETRO) for diversifying overseas supply chains.

Antigen tests can be carried out quickly and produce results on the spot. Despite these advantages, antigen tests have lower sensitivity than PCR tests and there are growing needs for the improvement of their sensitivity. From their advantages, antigen tests are now being considered globally for use not only at hospitals but also at airports, event venues and other premises as economic activities begin to resume. This has created the need for ensuring stable supply of antigen test kits.

From October this year, Fujifilm and the Public University Corporation Yokohama City University (Kanagawa, Japan) jointly develop the rapid and simple antigen test kit for SARS-CoV-2 using silver amplification immunochromatography method, which is Fujifilm’s proprietary highly-sensitive detection technology. The test kit is due to be produced at Fujifilm’s Ashigara Site in the Kanagawa Factory. However, in anticipation for the product’s global deployment in the future, FUJIFILM YUWA in Vietnam will start gradually reinforcing its production facilities next year to ensure supply stability for the test kit.

Other Avigan/COVID-19/Hydro Ag +/Fujifilm Biomedical Coverage ( 123456789, 101112131415161718192021222324252627282930313233, 34)

Please don’t forget to follow us on FacebookTwitterInstagramYouTube

Plus our owners’ groups
Fujifilm GFX Owners Group
Fujifilm X-H Owners Group
Fujifilm X-T Owners Group
Fujifilm X-S Owners Group
Fujifilm X-Pro Owners Group
Fujifilm X-E Owners Group
Fujifilm X-A Owners Group
Fujifilm X100 Owners Group

This entry was posted in Press releases and tagged , , , , , , . Bookmark the permalink. Trackbacks are closed, but you can post a comment.
  • FCC disclosure statement: this post may contain affiliate links or promotions that do not cost readers anything but help keep this website alive. As an Amazon Associate I earn from qualifying purchases. Thanks for your support!